Zhong Guo Jing Ji Wang·2026-03-28 05:20Group 1 - The Beijing Stock Exchange accepted Ruijian Medical's application for public offering on March 31, 2025, but has now decided to terminate the review process following the company's request to withdraw its application [2] - Ruijian Medical specializes in the research, production, and sales of blood purification products, focusing on providing diverse and stable quality products for end-stage renal disease patients [2] - The company originally planned to issue up to 43,000,000 shares, with a potential total of 49,450,000 shares including an over-allotment option, aiming to raise 482 million yuan for various blood purification projects [4][6] Group 2 - The controlling shareholder of Ruijian Medical is Puhua Heshun, which holds 50.55% of the voting rights, significantly influencing the company's management decisions [3] - Yufeng Liu, the ultimate controlling shareholder of Puhua Heshun, has significant influence over Ruijian Medical's shareholder meetings and decisions due to her ownership structure [3] - The company has a joint actual controller relationship between Yufeng Liu and Pu Zhongjie, with Liu being the mother-in-law of Zhongjie, which affects the governance of the company [3]